HHS sets interim enforcement discretion for 503A compounding of six peptides
The US Department of Health and Human Services announced in the Federal Register, as of October 30, 2026, a draft enforcement discretion policy under which it does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding six listed peptide bulk drug substances under section 503A of the FD&C Act.
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide based on a fragment of a protein found in human gastric juice. Almost all of the evidence comes from rodent and cell studies.
Read the full guide →In 30 seconds
- HHS says it does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician compounding a drug product with a bulk drug substance listed in Appendix A of the policy.
- Appendix A names six substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, each with limits on route of administration set in Appendix B.
- The policy is interim: compounded drugs remain outside FDA approval, and the 503A bulks list is still being developed through rulemaking.
Why it matters
The policy sets out when HHS will not act, and the scope it describes is compounding with a peptide bulk drug substance that is not a component of an FDA-approved drug product, the subject of an applicable USP or NF monograph, or on the 503A bulks list codified at 21 CFR 216.23(a). The policy states that the Secretary of Health and Human Services determined that this limited enforcement-discretion policy will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients, and that it gives patients a more controlled alternative. According to the document, the Secretary determined that the policy "advances patient choice and freedom while appropriately protecting patient safety."
The Federal Register notice adds that HHS believes there is significant interest in the use of these peptides in compounding given the lack of availability of approved products. The policy does not loosen the rest of section 503A: it applies only where a list of conditions is met at the same time, including a valid patient-specific prescription and lot-level testing documented in a certificate of analysis.
How does the list compare with real use? Our tracker data shows that most users take these peptides in blends, which the single-ingredient rule leaves out.
The details
- Appendix A lists six peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.
- Each substance must have the identity and the limitations in route of administration described in Appendix B, where the identity includes but is not limited to the amino acid sequence, chemical structure, molecular weight and molecular formula.
- Routes differ by substance: BPC-157 acetate for subcutaneous, intramuscular, oral and topical dosage forms; TB-500 acetate for subcutaneous or intramuscular injectable dosage forms; Epitalon acetate for subcutaneous or intramuscular injectable dosage forms dispensed in intermittent courses; Semax free base for intranasal use; KPV acetate for topical and oral dosage forms; MOTS-c acetate for subcutaneous or intramuscular injectable dosage forms.
- The bulk drug substance must come from a facility registered under section 510 and be characterized and identified in a valid certificate of analysis that includes test results consistent with existing guidance-based criteria described by FDA. The policy says this helps provide assurance that what a compounder receives from a supplier is what it claims to be and has been tested for identity, purity, potency, and the absence of harmful contaminants such as endotoxins, heavy metals, microbial contamination, and impurities.
- The original manufacturer (not a later packer, repacker, labeler or distributor) must be registered with FDA under section 510, be in compliance with CGMP and other FD&C requirements, and have its physical location listed on the COA given to the 503A compounder. If the substance comes through an FDA-registered repacker, relabeler or reseller, that entity must itself have performed and documented vendor validation of the manufacturer and of the manufacturer's COA.
- Compounders report products compounded, serious adverse events and product quality issues to FDA and to the States where the products are compounded and sent (if different). Serious adverse events associated with the use of the compounded drug product in humans are reported regardless of whether or not considered drug related.
- Those serious adverse events and product quality issues go to FDA's MedWatch Safety Information and Adverse Event Reporting Program, which the policy says gives FDA and States an opportunity to act on emerging risks. The procedure for reporting adverse events and issues with the identity, strength, purity or quality of the product should, according to the policy, be detailed on the product labeling provided to the patient.
- Product reporting covers the active ingredient and its strength per unit, the original manufacturer of the active ingredient with the unique facility identifier, and the dosage form and route of administration.
- The compounded product must contain only a single Active Pharmaceutical Ingredient listed in Appendix A.
- Labeling must carry the statement: "This is a compounded drug product. Not for resale."
- For an oral dosage form, the compounder is expected to keep documentation confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans.
- The only drug delivery device co-packaged with or containing the compounded drug may be an FDA 510(k)-cleared syringe.
- Compounding must meet all other applicable FD&C Act requirements, including the ban on insanitary conditions and the patient-specific prescription requirement.
- Regulatory history, as given for BPC-157: the free base and the acetate were in Category 2 from September 2023 until April 22, 2026, neither the placement nor the removal changed their status under section 503A, CDER recommended against listing either form, and the Pharmacy Compounding Advisory Committee voted in favor of inclusion.
- Document details: a Notice of availability from the Office of the Secretary, HHS, Docket No. HHS-OASH-2026-0496, citation 91 FR 68526.
What it does not change
This is not an approval. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed, and the policy repeats that compounded drugs may pose risks to patients even when they serve an important medical need. HHS presents the document as a draft policy, and it is explicitly interim: it holds until a peptide bulk drug substance is addressed in a final rule as being included or not included on the 503A bulks list, which FDA is still developing through rulemaking. For BPC-157, CDER recommended against listing either form, and the policy notes that neither the Category 2 placement nor its removal changed the substances' status under section 503A. HHS also says it may revisit application of the interim policy, in whole or in part, if, among other things, a safety signal or product quality issue arises with a product within its scope.
What's next
Written comments can be submitted until two weeks after the date of publication in the Federal Register, via regulations.gov on Docket No. HHS-OASH-2026-0496; the Federal Register page lists a comment due date of 11/13/2026 for that docket, and records 18 comments received at Regulations.gov. HHS says public comments may provide additional evidence that FDA can consider in rulemaking to address some or all of the substances, and the enforcement policy stands while the 503A bulks list is built through that rulemaking.
What we don't know yet
The documents reviewed here do not give a date for a final rule, nor do they say whether any of the six substances will end up included on or excluded from the 503A bulks list. The sources also do not state how many pharmacies or physicians will compound under the policy, and they give no clinical efficacy findings for any of the six substances.
Products sold online as research peptides are not the medicines studied or approved in this news. A medicine is available in a country only after that country's medicines agency approves it.
Source documents
This article reports news for information only. It is not medical or legal advice and does not recommend any use or dose. Every fact comes from the source documents listed above.